Oncology Clinical Trial Briefings
Follow mechanism, trial design, endpoints and regulatory context across targeted therapy, ADCs, cell therapy and immuno-oncology. Get this by email →
Clinical Trials News
A daily, plain-language digest of new oncology and life-sciences clinical trials, with a weekly deep-dive roundup — every update linked to its trial registry or primary source.
Original data report
Oncology Trial Activity Index
Compare recruiting cancer-study mentions across 37 genes, inspect the method and download the underlying CSV.
How to interpret an oncology trial update
Start with the population: cancer type, stage, biomarker, prior therapy and eligibility criteria determine what a result can establish. Then inspect the phase, randomisation, comparator, endpoint definition, follow-up and safety population. A response rate from a single-arm early study answers a different question from progression-free or overall survival in a randomised trial.
Registry status is not proof of efficacy, a conference abstract may change before peer review, and an FDA approval applies only within its labelled indication. GeneAnalyses links trial biology to gene and pathway guides so readers can understand why a therapy was tested while keeping clinical conclusions inside the source boundaries.
Most-mentioned cancer genes
Read the dated top-ten snapshot and the limits behind the ranking.
EGFR-mutant NSCLC
Understand variant, testing and resistance context before reading an EGFR trial.
CDK4/6 inhibitor evidence
Connect trial endpoints with cell-cycle mechanism and resistance.
Checkpoint immunotherapy
Review PD-1, PD-L1, CTLA4 and biomarker limitations.